Raleigh Capital Management’s Charles River Laboratories CRL Stock Holding History

Raleigh Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7	Closed	-$1.05K	–	651
2025 Q1	$1.05K	Sell	7 -7	-50%	-$1.17K	﹤0.01%	454
2024 Q4	$2.58K	Sell	14 -3	-18%	-$578	﹤0.01%	806
2024 Q3	$3.35K	Buy	17 +14	+467%	+$2.91K	﹤0.01%	758
2024 Q2	$620	Buy	3 +1	+50%	+$227	﹤0.01%	893
2024 Q1	$542	Buy	+2	New	+$478	﹤0.01%	881
2023 Q4	–	Sell	-47	Closed	-$9.21K	–	1096
2023 Q3	$9.21K	Buy	+47	New	+$9.65K	﹤0.01%	552

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Raleigh Capital Management's CRL Position: Q2 2025 in Review

Raleigh Capital Management sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 7 shares — an estimated $1.05K sold.

Raleigh Capital Management first reported a position in CRL in Q3 2023 and held it in 6 quarters. The position peaked at $9.21K in Q3 2023. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

Raleigh Capital Management reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
Raleigh Capital Management sold 7 Charles River Laboratories shares in Q2 2025, an estimated $1.05K.
Raleigh Capital Management first reported a position in Charles River Laboratories in Q3 2023 and held it in 6 quarters.
Raleigh Capital Management's Charles River Laboratories position peaked at $9.21K in Q3 2023.
519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Raleigh Capital Management's 13F filing for Q2 2025, filed 17 Jul 2025.